Monsanto the disposition of product lines unrelated to agriculture. In 1985, Monsanto acquired G. D. Searle & Company, a life sciences company that focused on pharmaceuticals, agriculture and animal health. In 1993, its Searle division filed a patent application for Celebrex, which in 1998 became the first selective COX‑2 inhibitor to be approved by the U.S. Food and Drug Administration (FDA). Celebrex became a blockbuster drug and was often mentioned as a key reason for Pfizer's acquisition of Monsanto's pharmaceutical business in 2002. In 1994, Monsanto introduced a recombinant version of bovine somatotropin, brand-named Posilac. Monsanto later sold this business to
Electricity sector in India Board, Kerala State Electricity Board, and Gujarat Urja Vikas Nigam Limited. India's Ministry of Power administers Rural Electrification Corporation Limited and Power Finance Corporation Limited. These central government owned public sector enterprises provide loans and guarantees for public and private electricity sector infrastructure projects in India. Without the realistic assessment of required capacity addition, every major bank, whether in public or private sector, has encouraged the businessmen to install thermal power plants by offering substantial loans at 75% of over estimated costs on overrated plant capacities (literally loan more than 100% of actual project cost) which has led to stranded